Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva de Jongh

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Blood|August 4, 2018
Atypical basophiliaHenk-Jan Boiten, Eva de Jongh
Nederlands Tijdschrift Voor Geneeskunde|September 27, 2019
[D-dimer: how about it?]Naura S Elias, Eva de Jongh, Henricus J Vermeer
BMJ Case Reports|July 7, 2020
Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphomaPaul J Hengeveld, Eva de Jongh, Peter E Westerweel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2024
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014)Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, et al.
Leukemia & Lymphoma|March 14, 2020
Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphomaHánah N Rier, Hardjit Kharagjitsing, Joost van Rosmalen, et al.
The Patient|February 15, 2023
Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation StudyChristine Bennink, Marleen de Mul, Marjolein van der Klift, et al.
The Oncologist|July 21, 2022
Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with CancerHánah N Rier, Marieke C Meinardi, Joost van Rosmalen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell LymphomaSteven Wang, Marcel Nijland, Leonie Strobbe, et al.
Blood Cancer Journal|May 22, 2023
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patientsA Vera de Jonge, Erik van Werkhoven, Avinash G Dinmohamed, et al.
British Journal of Haematology|March 10, 2020
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trialJeanette K Doorduijn, Josee M Zijlstra, Pieternella J Lugtenburg, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Blood|August 4, 2018
Atypical basophiliaHenk-Jan Boiten, Eva de Jongh
Nederlands Tijdschrift Voor Geneeskunde|September 27, 2019
[D-dimer: how about it?]Naura S Elias, Eva de Jongh, Henricus J Vermeer
BMJ Case Reports|July 7, 2020
Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphomaPaul J Hengeveld, Eva de Jongh, Peter E Westerweel, et al.
European Journal of Cancer (Oxford, England : 1990)|November 30, 2024
Rituximab maintenance for patients with diffuse large B-cell lymphoma in first complete remission: Long-term results of the HOVON-84 randomized phase III study by the HOVON and the Nordic Lymphoma Group (clinical trial number: NTR1014)Pieternella Johanna Lugtenburg, Peter de Nully Brown, Bronno van der Holt, et al.
Leukemia & Lymphoma|March 14, 2020
Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphomaHánah N Rier, Hardjit Kharagjitsing, Joost van Rosmalen, et al.
The Patient|February 15, 2023
Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation StudyChristine Bennink, Marleen de Mul, Marjolein van der Klift, et al.
The Oncologist|July 21, 2022
Association Between Geriatric Assessment and Post-Chemotherapy Functional Status in Older Patients with CancerHánah N Rier, Marieke C Meinardi, Joost van Rosmalen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2025
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell LymphomaSteven Wang, Marcel Nijland, Leonie Strobbe, et al.
Blood Cancer Journal|May 22, 2023
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patientsA Vera de Jonge, Erik van Werkhoven, Avinash G Dinmohamed, et al.
British Journal of Haematology|March 10, 2020
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trialJeanette K Doorduijn, Josee M Zijlstra, Pieternella J Lugtenburg, et al.
Pageof 2